What Has Been The Evolution of the Cervical Cancer Diagnostics Market in Recent Years?
The cervical cancer diagnostics market has seen considerable growth due to a variety of factors.
• The market size for cervical cancer diagnostics has seen robust growth in the past few years. The market which is projected to escalate from $9.27 billion in 2024 to $9.85 billion in 2025, will advance at a compound annual growth rate (CAGR) of 6.2%.
This growth during the historic period has been influenced by factors such as increased awareness and screening programs, HPV vaccination, technological improvements, and an aging population.
What Are the Future Growth Projections for the Cervical Cancer Diagnostics Market?
The cervical cancer diagnostics market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the market size for cervical cancer diagnostics is anticipated to experience robust growth. The estimations suggest that it will escalate to $12.5 billion in 2029 with a compound annual growth rate (CAGR) of 6.1%.
Factors such as rise in HPV-related cancers, the emergence of new markets, advancements in molecular testing, telemedicine, and remote screening are driving this growth during the forecast period. The primary trends in the stated period encompass HPV testing, liquid-based cytology, automation, digital pathology, and screen-and-treat programs.
What Are The Core Factors Supporting Growth In The Cervical Cancer Diagnostics Market?
The increased use of diagnostic tests for early detection of cervical cancer is anticipated to influence the cervical cancer diagnostics market positively. The augmented awareness about cervical cancer among women, together with the focus laid by global cancer organizations and government bodies on early screening to identify and prevent cervical cancer, adds fuel to the market growth. For example, the Centers for Disease Control and Prevention, a US-based government agency, reported in July 2024 that there were 12,536 new diagnoses of cervical cancer in 2021, and the disease led to 4,051 deaths among women in 2022. The escalating uptake of diagnostic tests for cervical cancer and the focus on early detection stimulates the expansion of the cervical cancer diagnostics market.
What Are The Major Segments Within The Global Cervical Cancer Diagnostics Market?
The cervical cancer diagnostics market covered in this report is segmented –
1) By Diagnostic Test: Pap Smear Test, HPV Test, Colposcopy, Biopsy and Endocervical Curettage, Other Diagnostic Tests
2) By Age Group: Below 21, Age between 21 to 29, Age between 30 to 65, Above 65
3) By End User: Hospitals, Specialty Clinics, Cancer And Radiation Therapy Centers, Diagnostic Centers
Subsegments:
1) By Pap Smear Test: Conventional Pap Smear, Liquid-Based Pap Smear
2) By HPV Test: DNA-Based HPV Test, RNA-Based HPV Test, Hybrid Capture HPV Test, Other HPV Tests
3) By Colposcopy: Standard Colposcopy, Digital Colposcopy, Optical Colposcopy
4) By Biopsy And Endocervical Curettage: Punch Biopsy, Endocervical Curettage (ECC), Cone Biopsy, Colposcopic Biopsy
5) By Other Diagnostic Tests: Visual Inspection With Acetic Acid (VIA), Cervical Cytology Testing, Blood Tests, Other Specialty Tests
Pre-Book The Cervical Cancer Diagnostics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The Cervical Cancer Diagnostics Market?
In an effort to improve accessibility to screening and early detection rates, leading companies in the cervical cancer diagnostics market have been concentrating on creating technologically superior solutions, such as HPV self-collection methods for cervical cancer. Humans self-collecting their samples for HPV (human papillomavirus) testing, the root cause of cervical cancer, is what the HPV self-collection solution entails. F. Hoffmann-La Roche AG, a Swiss pharmaceutical company, was granted FDA consent for its HPV self-collection solution in May 2024 as an instance. This significant breakthrough in cervical cancer screening enhances availability, particularly for those who belong to underprivileged communities. Women can now discreetly gather vaginal samples for analysis using Roche's Cobas molecular HPV test. This aligns with the World Health Organization's ambition to eradicate cervical cancer by 2030. The IMPACT trial verified the effectiveness of this solution across diverse population groups, prompting its approval.
Who Are the Key Players In The Cervical Cancer Diagnostics Market?
Major companies operating in the cervical cancer diagnostics market include:
• Abbott Laboratories
• Becton Dickinson and Company (BD)
• Bio-Rad Laboratories Inc.
• F. Hoffmann-La Roche Ltd.
• Hologic Inc.
• QIAGEN N.V.
• Quest Diagnostics Incorporated
• Siemens Healthineers AG
• Zilico Ltd.
• Guided Therapeutics Inc.
• Thermo Fisher Scientific Inc.
• Carl Zeiss AG
• OncoHealth Corporation
• Arbor Vita Corporation
• Micromedic Technologies Ltd.
• Trovagene Inc.
• Roche Diagnostics
• Nucleix Ltd.
• BGI Genomics Co. Ltd.
• Cepheid
• Exact Sciences Corporation
• Guardant Health Inc.
• Invitae Corporation
• Natera Inc.
• NeoGenomics Laboratories Inc.
• PerkinElmer Inc.
• Sysmex Corporation
• Veracyte Inc.
• Zymo Research Corporation
What Is The Most Dominant Region In The Cervical Cancer Diagnostics Market?
North America was the largest region in the cervical cancer diagnostics market in 2023 Asia-Pacific was the second largest region in the cervical cancer diagnostics market. The regions covered in the cervical cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
